250 mg LX1033 tablets
LX1033.1-201-IBS
Phase 2 small_molecule completed
Quick answer
250 mg LX1033 tablets for Irritable Bowel Syndrome is a Phase 2 program (small_molecule) at LEXICON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LEXICON PHARMACEUTICALS, INC.
- Indication
- Irritable Bowel Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed